Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals — Investor Presentation (June 2019)

25 slides from Aerie Pharmaceuticals's investor presentation, Jun 13, 2019

  1. Slide 1: Company Overview Investor Presentation June 2019

    Company Overview Investor Presentation June 2019 Exhibit 99.1

  2. Slide 2: Disclaimer and forward-looking statements

    The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by reference to repor

  3. Slide 3: Aerie Overview

    For Investor Use Aerie Overview Rhopressa® and Rocklatan® have not been approved by any regulatory authority other than the FDA. Additional potential Rhopressa® indications are being considered for further study and are not labeled indications. AR-13503 and AR-1105 are pre-clinical molecules and hav

  4. Slide 4: Rhopressa: Market Perspective

    For Investor Use Rhopressa®: Market Perspective - ~$3B Market, 35M TRx, 52M bottles - Half of volume first-line (PGAs) - Half of volume 2-3X/Day Adjuncts - New drug class - Once-daily dosing directed at site of pathology: the trabecular meshwork - Consistent IOP reduction over 12 months and across a

  5. Slide 5: Rhopressa Formulary Coverage Increasing

    For Investor Use Rhopressa® Formulary Coverage Increasing As of 6/01/19: ~90% of Commercial Lives Covered ~75% Medicare Part D Lives Covered Majority Preferred Tier 2 Equivalent Coverage Commercial and Medicare Part D ------------Commercial------------- -----------Medicare Part D--------- Rhopressa®

  6. Slide 6: Weekly IQVIA Rx's and Bottles: Rhopressa U.S. Launch Update

    For Investor Use Weekly IQVIA Rx’s, IQVIA Bottles and Sales-Out Bottles: Actual Sales-Out to Pharmacies and Restated IQVIA data as of 5/24/19 *Actual bottles dispensed exceed Rx’s due to extended supply plans (e.g., 90 days’ supply) 11,308 6,983 8,893 Note: IQVIA reporting changed for all reported p

  7. Slide 7: Active Engagement at Key Conferences

    For Investor Use Active Engagement at Key Conferences American Glaucoma Society (AGS) March 2019 American Society of Cataract and Refractive Surgeons (ASCRS) May 2019 Association of Research in Vision and Ophthalmology (ARVO) April/May 2019 European Glaucoma Society (EGS) Florence, May 2018 European

  8. Slide 8: Rocklatan Combination Product

    For Investor Use Rocklatan® Combination Product Candidate Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Positioning as First Line Therapy: Benefits of Rhopressa® while also targeting the secondary drain Achieved statistical superiority to market-leading latanoprost At each

  9. Slide 9: Rocklatan Efficacy and Safety

    For Investor Use Rocklatan® Efficacy and Safety Efficacy: Rocklatan® demonstrated statistical superiority over its components (market-leading PGA latanoprost and Rhopressa®) in Mercury 1 and 2 Phase 3 trials, at all measured time points Consistent incremental IOP-reduction over latanoprost and Rhopr

  10. Slide 10: Rocklatan Responder Analysis

    For Investor Use Rocklatan® Phase 3 Month 12 Responder Analysis: Goal is to Achieve Lowest IOP Possible At Month 12: % of Patients with IOP Reduced to 18 mmHg or Lower *p<0.05, **p<0.01, ***p<0.0001 ++Data on File Based on Mercury 1 Interim Analysis 2 Rocklatan® has not been approved by any regulato

  11. Slide 11: Rocklatan Launch Update

    For Investor Use Rocklatan® Launch Update Rocklatan® launched May 1, 2019 First fixed-dose combination glaucoma medication including a prostaglandin analog introduced in the US Rocklatan® launch national broadcast included over 60 sites and 1,100 participants 60% commercial non-preferred coverage at

  12. Slide 12: Weekly IQVIA Rx's: Rocklatan vs Rhopressa Launch

    For Investor Use Weekly IQVIA Rx’s, IQVIA Bottles and Sales-Out Bottles: Rocklatan® U.S. Launch compared to Rhopressa® U.S. Launch *Actual bottles dispensed exceed Rx’s due to extended supply plans (e.g., 90 days’ supply) Rhopressa® and Rocklatan® have not been approved by any regulatory authority o

  13. Slide 13: Expanding Aerie Franchise: Europe and Japan

    For Investor Use Expanding Aerie Franchise: Europe and Japan Europe (2018 Europe “Big 5” Glaucoma Market: 92M units per year, 1.8X U.S. units) MAA accepted for Rhokiinsa® (Rhopressa®) in October 2018, expect 12-month review Mercury 3: 6-month safety and 90-day efficacy registration trial comparing R

  14. Slide 14: Europe Glaucoma Market

    For Investor Use Europe Glaucoma Market: Aerie Expects to Commercialize on Its Own (if approved) PGA: Prostaglandin Analogue; BB: Beta Blocker; AA: Alpha Agonist; CAI: Carbonic Anhydrase Inhibitor Sources: IMS Analytics Link at ex-manufacturer price level- March 2019. *TRx calculated from IQVIA unit

  15. Slide 15: Japan Glaucoma Market

    For Investor Use Japan Glaucoma Market: Aerie Expects to Partner for Commercialization (if approved) PGA: Prostaglandin Analogue; BB: Beta Blocker; AA: Alpha Agonist; CAI: Carbonic Anhydrase Inhibitor Sources: IQVIA Analytics Link at ex-manufacturer price level – March 2019. *TRx calculated from IQV

  16. Slide 16: Advancing the Pipeline

    For Investor Use Advancing the Pipeline Rhopressa® Research Targets 24-hour IOP reduction Potential in normal tension glaucoma (successful Pilot Phase 2 for Japan) Aqueous humor dynamics (trabecular outflow, episcleral venous pressure) Pseudoexfoliative glaucoma Corneal healing Sustained-Release Ret

  17. Slide 17: Retinal Eye Diseases – Aerie's Next Chapter

    For Investor Use Retinal Eye Diseases – Aerie’s Next Chapter Bringing Small Molecule Therapy to Back of the Eye Most retinal drugs in use and in pipeline are protein therapeutics Longer half-life allows monthly to bimonthly IVT injections Protein therapeutics address limited number of extracellular

  18. Slide 18: 2018 U.S. Retinal Disease Market

    For Investor Use 2018 U.S. Retinal Disease Market 2018 Sales: $6.0B 2018 Unit Sales: 7.3MM Sources: Mixture of public information, IQVIA, Market-Scope and estimates – March 2019

  19. Slide 19: Aerie's Innovation in Retinal Disease

    For Investor Use Aerie’s Innovation in Retinal Disease Small Molecule Drug Candidates Proprietary Drug Delivery Technology Bio-erodible, sustained-release implant for intravitreal injection DSM PEA Polymer PLGA PRINT® Mfg AMD DME RVO Dry AMD/GA Glaucoma Others Aerie Kinase Library Non-Aerie drug can

  20. Slide 20: Retinal Eye Disease Unmet Needs in AMD and DME

    For Investor Use Retinal Eye Disease Unmet Needs in AMD and DME Need new treatments to address disease mechanisms beyond VEGF Complex pathology cannot be addressed by a single drug class Many patients do not achieve and/or maintain sufficient efficacy AMD: Anti-VEGF efficacy often lost after 5–7 yea

  21. Slide 21: Lead Retina Products

    For Investor Use Lead Retina Products AR-1105 (Dexamethasone) Implant Indications: retinal vein occlusion (RVO) and DME Target product profile vs. Ozurdex® Longer duration of efficacy (6 mo vs 3 mo) Improved administration due to smaller needle Potential for fewer adverse effects due to lower peak d

  22. Slide 22: AR-13503 Efficacy Similar to Eylea in PDR Model

    For Investor Use Preclinical AR-13503 Provides Efficacy Similar to Eylea® in a Proliferative Diabetic Retinopathy Model Oxygen-induced retinopathy (OIR) mouse model - PDR Administration: Intraperitoneal QD Data on File For more information on Eylea® please see the product webpage https://www.eylea.u

  23. Slide 23: AR-13503 Synergistic to Eylea in Mouse Model

    For Investor Use AR-13503 Synergistic to Eylea® in Mouse Model of Proliferative Diabetic Retinopathy Oxygen-induced retinopathy (OIR) mouse model - PDR -40% * Administration: Intraperitoneal QD * : p<0.01 *** : p<0.0001 -60% % of Total Area Neovascular Area (+SEM) Data on File Sub-optimal dose level

  24. Slide 24: ROCK: Additional Indications Beyond Ophthalmology

    For Investor Use ROCK Commencing screening for additional indications beyond ophthalmology ROCK inhibition should have potential in: Pulmonary health, including pulmonary fibrosis and bronchial asthma Dermatology indications Cancer Others Relationship tree of human kinases. TK, TKL, STE, CK1, AGC, C

  25. Slide 25: Summary Key Priorities

    For Investor Use Summary Key Priorities Rhopressa®: Continued successful launch execution Rocklatan®: FDA approved on March 12, 2019, successful launch execution Globalization Strategy Europe/Japan clinical path and commercialization strategy Ireland Manufacturing Facility Research Initiatives Rhopr

Aerie Pharmaceuticals — Investor Presentation (June 2019) on 6ix